The coexistence of α-synuclein and tau aggregates in several neurodegenerative disorders, including Parkinson's disease (PD) and Alzheimer's disease (AD), raises the possibility that a seeding mechanism is involved in disease progression.
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Introduction
The misfolding of tau and α-synuclein is a key initiation event in a large group of neurodegenerative disorders. Compelling evidence suggests that misfolded proteins may seed the conformational change of other amyloidogenic proteins in a prion-like manner. The discovery of tau and α-synuclein aggregates in the same cell suggests that protein seeding may occur in vivo (1) . This could explain why tau and α-synuclein aggregates coexist in pathologies such as Alzheimer's disease (AD) (2) (3) (4) , Down syndrome (5) , Parkinsonism dementia complex of Guam (6) , Lewy Body Dementia (LBD) (7-10) and Parkinson's disease (PD) (11) .
Studies from transgenic mice support the hypothesis that α-synuclein influences tau deposition. The overexpression of mutant human α-synuclein (A53T) in mice was associated with abundant tau-positive threads, grains, spheroids and pre-tangles in several brain regions (12) , and mice overexpressing human wild type α-synuclein spontaneously developed tau pathology in an age-dependent manner (13) . Additionally, recombinant tau and α-synuclein are capable of inducing fibrillization of each other (12) and exposure of cells in culture to exogenous fibrils of recombinant tau and α-synuclein lead to development of large inclusions (14, 15) .
Remarkably, since large inclusions comprised of tau and α-synuclein do not correlate with disease progression, this casts doubt on the toxicity of stable fibrils, and highlights the oligomeric forms of both proteins to be responsible for neuronal and synaptic loss (16, 17) .
Moreover, both tau and α-synuclein oligomers have been described in PD and LBD (11, 18, 19) , while tau oligomers are an established component of tauopathies including AD (20) (21) (22) and progressive supranuclear palsy (PSP) (23) . However, the pathological consequences of the synergy between tau and α-synuclein oligomers have yet to be determined.
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A C C E P T E D ACCEPTED MANUSCRIPT 4 In order to investigate the role of α-synuclein in the tau aggregation pathway, we performed a set of experiments using recombinant tau and α-synuclein oligomers to seed tau aggregation, as well as brain-derived tau oligomers isolated from PSP (a pure tauopathy) and brain-derived complexes of α-synuclein/tau oligomers from PD cases. Our findings revealed that seeds of α-synuclein potentiate tau oligomer toxicity in SH-SY5Y and CV-1 cells overexpressing tau, while promoting spine retraction in primary neurons. Surprisingly, seeds of α-synuclein induced a distinct toxic tau oligomeric strain that avert tau fibrillization. Meanwhile, PD-derived α-synuclein/tau oligomers administered into Htau mouse brains accelerated endogenous tau oligomer formation and neuronal loss, when compared to injection of PSP-derived tau oligomers. In summary, our findings suggest that α-synuclein shifts the tau aggregation pathway while potentiating tau oligomer toxicity, thereby driving disease progression and spread of pathology.
Materials and Methods
Aggregation assay
Recombinant wild-type (Wt) 2N4R tau (tau 441) and α-synuclein were expressed in Escherichia coli and purified as described previously (24, 25) . Under standard conditions, recombinant full length tau 441 AA (4-8 µM) was incubated with seeds of preformed tau oligomers, seeds of preformed α-synuclein oligomers or heparin in Assembly Buffer (10 mM HEPES, pH 7.4, 100 mM NaCl, and 5 mM dithiothreitol) at either room temperature or 37 °C for 3-6 h. Three independent replications were performed for each experimental setting. Figure S1G ). Western blot analyses with T22 (to detect tau oligomers) and Tau5 (to visualize total tau) antibodies showed an increase in high molecular weight tau aggregates above 250 kDa when using seeds of tauO, but not α-synO (*p<0.01, n=3; df=4; Multiple t-test non-parametric; Supplementary Figure S1A-C).
In order to investigate tau oligomers strains' properties, CV-1 cells, which do not express endogenous tau (27) , were transfected with full length human tau linked to yellow fish (YFPtau). Live cell imaging of CV-1 cells revealed that α-synO seeds induced a distinct tau oligomeric strain that altered cell morphology and increased cell death compared to tau seeded with preformed tauO ( Figure 1C -F). No effect was shown in cells exposed to vehicle (PBS), monomeric tau (data not shown) or α-synuclein seeds alone (Supplementary Figure S1D -E).
The striking results found in CV-1 cells exposed to α-synO seeds were confirmed by measuring luminescence corresponding to ATP as a measure of cell toxicity (Tau/α-synO **p<0.006;
Tau/tauO *p<0.03; Error bars, SEM, n=4; One-way ANOVA, Tukey's multiple comparisons test; Figure 1F ). Immunocytochemical analyses using tubulin and T22 antibodies confirmed a reduced number of cells, as well as abnormal cellular morphology ( Figure 1G -O) after treatment with tau cross-seeded with α-synO. No evidence of intracellular deposition was observed in any of the treatments.
We next investigated the toxicity of tau oligomeric strains on the human neuroblastoma cell line SH-SY5Y differentiated with retinoic acid. As expected, we found increasing cell death in cells exposed to both tau oligomers preparation (TauO/tauO, ***p<0.0004; TauO/α-synO, ****p<0.0001; n=4; One-way ANOVA, Tukey's multiple comparisons test) (Supplementary To further investigate the effects of tau aggregates, primary cortical neurons obtained from Htau mouse embryos were exposed to vehicle (PBS) and tau oligomeric strains (seeded with tauO or with α-synO) for 24 hours ( Figure 1P -X). Live cell imaging revealed a dramatic dendritic spine retraction in cells treated with tau oligomers induced by α-synO seeds, but not tauO seeds or vehicle (data not shown). Immunofluorescence staining using PSD95 antibody to visualize synapses confirmed the reduction of dendritic spines (PSD95 puncta) ( Figure 1P 
Seeds of α-synuclein shift the tau aggregation pathway, extending the lifespan of the toxic tau conformation
To further investigate the ability of α-synuclein oligomers to induce tau fibrillization, we performed kinetic analyses using Thioflavin S (ThS) ( Figure 2 ). Fluorescence intensity from ThS ( Figure 2A ) as well as dot blot analyses ( Figure 2B ) showed that tau seeded with tauO or α- AFM images taken at 360 hours after seeding showed that tau seeded with tauO assembled into short fibrils ranging from ~150 to 300 nm in length ( Figure 2C . Surprisingly, we found that tau cross-seeded with α-synO retained its toxicity as demonstrated by the reduced number of viable CV-1 cells transfected with YFP-tau, compared to tauO or PBS (**p<0.006, *p<0.03, respectively; One-way ANOVA, Tukey's multiple comparisons test;
Supplementary Figure S2A -D). As we previously reported (28), tau fibrils had a minimum effect on cells in culture (data not shown). Furthermore, cells exposed to tau/α-synO appeared to exhibit cell membrane retraction as indicated by their compact shape, possibly preceding cell death (Supplementary Figure S2E -M). These findings suggest that seeds of oligomeric αsynuclein induce a stable distinct toxic oligomeric tau strain, thereby forming a kinetic trap and preventing tau fibril formation.
Complexes of α-synuclein/tau oligomers isolated from PD cases accelerate endogenous tau oligomer formation in Htau mouse brain.
A strong argument in PD and LBD is that α-synuclein influences tau misfolding, thus suggesting a possible interaction between them. We have recently shown that α-synuclein and tau oligomers exist in complex in PD and LBD cases (11) . However, whether these complexes can propagate tau misfolding and contribute to disease progression has not yet been investigated.
In order to gain further insight into the synergism between tau and α-synuclein, we isolated oligomers of α-synuclein in complex with tau oligomers from PD brain cases (PD α-synO/tauO) and compared them with tau oligomers isolated from PSP, a pure tauopathy (PSP tauO; Supplementary Table S1 ). Brain-derived tau oligomers were immunoprecipitated using our antitau oligomer antibody, T22, while PD oligomeric complexes were immunoprecipitated with the anti-α-synuclein oligomer antibody, F8H7, as well as T22, as previously described (11) Studies from our group and others have previously shown that injection of brain-derived oligomers from AD cases exacerbates tau pathology in the brain (29, 30) ; therefore, in order to evaluate the effects of brain-derived oligomers from PSP and PD administered in the Htau mouse brain, immunohistochemical analysis was performed using the neuronal marker NeuN ( Figure 3B ,C,F,G,J,K), as well as immunofluorescence using T22 antibody ( Figure 3D ,H,L).
Unbiased stereology analysis showed a significant neuronal loss at the hippocampus in mice receiving PD α-synO/tauO when compared to PSP-tauO or PBS injection (*p<0.03; n=6, Oneway ANOVA Bonferroni's post hoc comparisons test; Figure 3N ). In contrast, levels of tau oligomers increased in both mice injected with PD α-synO/tauO and PSP-tauO (*p<0.03, n=8, One-way ANOVA, Bonferroni's post hoc comparisons test; Figure 3O ). To further determine the levels of tau oligomers and total tau in mice brain, brain homogenates PBS soluble fractions were measured by ELISA analysis with T22 and Tau 5 antibodies. Consistent with the stereology analysis, tau oligomers levels increased in mice receiving PD α-synO/tauO Tau is known to be hyperphosphorylated in Htau mice, therefore, we investigated the phosphorylation status of tau in mice injected with brain-derived oligomers or PBS.
Immunostaining analysis was performed using AT180 antibody, for the detection of tau phosphorylated at the Thr231 epitope, a marker of early tau aggregation ( Figure 3E , I, M). This analysis revealed increased levels of phospho-tau not only at the injection site, the hippocampus, but also in the cortex (data not shown), suggesting the propagation of misfolded tau in mice injected with brain-derived oligomers compared to vehicle (*p<0.04; n=4, One-way ANOVA, Bonferroni's post hoc; Figure 3P ). Tau oligomers are known to be early aggregates responsible for the spread of pathology (29) . To further analyze these findings, a Western blot analysis of brain homogenate using T22 antibody confirmed increased levels of tau oligomers in mice injected with PD α-synO/tauO compared to PSP-tauO and control treatment (**p<0.003, *p<0.02; One-way ANOVA, Tukey's multiple comparison test; Figure 3Q ,R). We then investigated neuronal loss in mice injected with PD α-syn/tauO using Western blot by measuring active caspase-3 levels, which have been shown to be involved in the development of tau neuropathology (31) . Increased caspase-3 levels were found in PD α-synO/tauO when compared to PSP-tauO and PBS treatments (**p<0.006, n=3; One-way ANOVA, Tukey's multiple comparison test; Figure 3Q , S). Thus, increased tau oligomers correlated with increased cell loss in PD-derived oligomer-treated mice.
PD-like pathology in Htau mice injected with PD brain-derived α-synuclein/tau oligomers
Previous studies have shown that injection of recombinant fibrils of α-synuclein induce PD-like aggregates in wild type mice (14, 32, 33) . These observations prompted us to investigate the formation of PD-like pathology in Htau mice injected with α-synuclein oligomers. We conducted a nonbiased stereology analysis of brain sections immunostained with LB509, a pan-αsynuclein antibody ( Figure 3T-W) . Deposits of α-synuclein were found in Htau mice receiving PD-α-synO/tauO outside the injection site, the hypothalamus, resembling a Lewy body inclusion in a human diseased brain ( Figure 3V ). Although several sections from different brains were analyzed, few Lewy body-like deposits were found (*p<0.01 n=5; One-way ANOVA, Tukey's multiple comparisons test). Our findings suggest that PD brain-derived α-synO/tau oligomer complexes might initiate endogenous α-synuclein deposition into Lewy body-like inclusions.
However, we cannot ignore the possibility that seeds of α-synuclein could have been dissociated from these complexes, promoting the formation of large intracellular deposits. Supplementary Figure 3 ). All these finding suggested that while PSP tauO increased tau deposition in Htau mice brain, PD-α-syn/tauO may delay or evade NFT formation in vivo.
Discussion
Oligomeric tau and α-synuclein appear to play an important role in the pathogenesis of a group of neurodegenerative diseases including Parkinson's and Alzheimer's diseases. The overlap between tau and α-synuclein in several brain pathologies suggests that protein seeding may be involved. While the toxicity of tau and α-synuclein is well-documented in cell culture (23, 29, 34) and in rodents (30, 35) , the pathological consequences of the interaction between the two proteins remain unknown.
This study provides evidence, for the first time, that α-synuclein potentiates tau oligomer toxicity in vitro and in Htau mouse brain. Our findings demonstrate that oligomeric α-synuclein induces tau misfolding into a unique oligomeric toxic strain that averts tau fibril formation.
Exogenous fibrils of recombinant tau or α-synuclein can be taken up in cells and seed the fibrillization of tau and α-synuclein, respectively. Tau enhances α-synuclein toxicity in cells in culture (14, 36) , while having devastating effects in fruit flies (37) . Additionally, α-synuclein oligomers disrupt microtubule stability, affecting the transport of cargo proteins through the microtubule network (38) . In our study, the deleterious effects of tau aggregates induced by αsynuclein oligomers in cultured cells do not rely on α-synuclein seeds directly, as treatment of cells with an equivalent amount of α-synuclein oligomers alone was not sufficient to alter cell morphology. A possible explanation for the differences in toxicity between both tau oligomer M A N U S C R I P T
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13 preparations is the fact that tau seeded with preformed tau oligomers contained some prefibrillar oligomers arranged in a chain, which is not the case in tau cross-seeded with α-synuclein oligomers, implying that self-protein interaction may facilitate fibril formation. Previous data showed that 3R-tau can seed 3R-tau but not 4R-tau fibril formation, suggesting that homogenous protein populations are prone to assemble into large aggregates, while crossspecies proteins are not (39, 40) .
Our findings propose that a tau strain induced by α-synuclein oligomers averts fibril formation. Recently, Fang et al, showed that TDP-43 oligomers can cross-seed amyloid-β misfolding into oligomers, but not fibrils (41). Interestingly, in our study we did not observe large intracellular aggregate formation in any of the cell lines used, which may infer that fibril formation follows a different aggregation pathway or may require a longer exposure time.
Remarkably, while the toxicity of fibrils is questioned, it has become more accepted that oligomers may play a role in the spread of disease pathology and neurodegeneration. A recent study using a biosensor cell line showed that tau seeding occurred before accumulation of insoluble tau (42) . Moreover, we have shown that brain-derived tau seeds can spread tau pathology throughout the brain, inducing the misfolding of endogenous tau (29, 30) . These observations demonstrated that oligomeric forms of tau can propagate pathology.
In this study, we found that 14 months post icv injections of Htau mice with brain-derived PSP tau oligomers or PD oligomers containing complexes of α-synuclein and tau, the mixed oligomer populations induce neuronal loss and behavioral deficits. Our previous findings have shown that brain derived tau oligomers induced cognitive decline and synaptic and mitochondrial dysfunction in wild type mice, while accelerating endogenous tau misfolding in Htau mice (43) .
Here, we found that PD brain derived oligomers containing complexes of α-synuclein and tau induced neuronal loss and increase in tau oligomers levels, coinciding with the onset of M A N U S C R I P T
14 cognitive decline and motor deficits in Htau mice. Furthermore, PD brain derived oligomeric complexes accelerate endogenous tau aggregation, thus implying that these brain derived complexes are likely responsible for disease onset. While evidence has suggested that the onset of clinical symptoms in AD and PSP patients correlate with elevated levels of tau oligomers (20, 22, 23) , it is difficult to precisely elucidate how PD brain derived oligomeric complexes induce tau aggregation. In support of these findings, PD patients that develop tau pathology are associated with dementia onset and poor prognosis (44) , thus suggesting that a synergy between tau and α-synuclein may enhance clinical phenotype. In our study, αsynuclein/tau oligomer complexes seem to be more stable and pathologically relevant, given the capability to propagate endogenous tau oligomer formation and cell death in Htau mouse brain.
Previous reports have found phospho-tau and α-synuclein in the same NFT, Lewy body or neurite from PD and LBD cases (45, 46) . In a recent study from our group, we demonstrated that α-synuclein and tau oligomers formed complexes in PD and LBD brains (11) . In a separate study, we showed that α-synuclein interacts with oligomers of other proteins such as amyloid-β to form hybrid oligomers in AD brains, suggesting that protein interaction at oligomeric levels occurs broadly in the human brain (47) . Thus, our findings propose that extending the lifespan of oligomeric tau may be a key contributor to the spread of a toxic tau conformation, as well as the misfolding of functional tau. Although oligomers have been considered intermediate to fibril formation, our data suggests that they may follow an independent pathway.
Previous studies have shown that fibrils can seed fibril formation in vitro as well as in vivo (48).
Our findings demonstrated that oligomeric assemblies of α-synuclein protein templated tau oligomer formation and thus enhanced toxicity and prevented tau fibril formation in vitro. These findings are consistent with our in vivo study where intracerebrally infused small amount of brain-derived α-synuclein oligomers (PD α-synO/tauO) propagated tau oligomer formation while accumulating less fibrillar tau compared to Htau mice receiving PSP brain derived oligomers.
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These observations suggested that PD α-synO/tauO complexes may be involved in delaying tau oligomer assembly into NFTs. The fact that PD-like α-synuclein aggregates, the so-called Lewy bodies, were found in the hypothalamus area indicated that α-synuclein/tau complexes migrated far from the injection site.
To our knowledge, this is the first demonstration that tau cross-seeded with α-synuclein oligomers induces tau aggregation and extends the toxic lifespan of tau oligomers by preventing them from undergoing transformation to a less toxic state, thus facilitating the propagation of endogenous tau protein in vivo. Overall, our findings suggest that the protein seeding mechanism is key to enhancing disease pathology; therefore, small doses of α-synuclein oligomeric seeds may have grave pathological consequences in the brain. 
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